new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)





Similar
Filing Names

Chiesi Farmaceutici S p a
Chiesi Farmaceutici S p a_20100107
Chiesi Farmaceutici S p a_20100128
  

Chiesi Farmaceutici S p a patents

Recent patent applications related to Chiesi Farmaceutici S p a. Chiesi Farmaceutici S p a is listed as an Agent/Assignee. Note: Chiesi Farmaceutici S p a may have other listings under different names/spellings. We're not affiliated with Chiesi Farmaceutici S p a, we're just tracking patents.

ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "C" | Chiesi Farmaceutici S p a-related inventors




Date Chiesi Farmaceutici S p a patents (updated weekly) - BOOKMARK this page
04/13/17Novel compounds
04/06/17Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
03/30/17Clevidipine nanoparticles and pharmaceutical compositions thereof
03/23/17Combination therapy for copd
03/23/17Aerosol inhalation device
03/09/17Pharmaceutical solution formulations for pressurised metered dose inhalers
12/08/16Process for preparing carrier particles for dry powders for inhalation
12/01/16Aminoester derivatives
12/01/16Aminoester derivatives
12/01/16Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
11/10/16Crystalline microparticles of a beta-agonist coated with a fatty acid
11/10/16Process for the preparation of a pde4 inhibitor
11/10/16Aminoester derivatives
10/20/16Stable pressurized aerosol solution composition of glycopyrronium bromide and formoterol combination
10/20/16Stable pressurized aerosol solution composition of glycopyrronium bromide and formoterol combination
10/20/16Chromene derivatives as phoshoinositide 3-kinases inhibitors
09/29/16Particle size reduction of an antimuscarinic compound
09/15/16Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation
09/15/16Improved the administration of a pulmonary surfactant by atomization
09/01/16Novel compounds
08/18/16Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
08/11/16Kinase inhibitors
07/07/16Novel polymorphs and salts
06/16/16Novel compounds
04/21/16Derivatives of [1, 2, 4] triazolo [4, 3 - a] pyridine as p38 - map kinase inhibitors
03/17/16Pyridazinone derivatives as phoshoinositide 3-kinases inhibitors
01/21/16Kinase inhibitors
01/21/16Kinase inhibitors
01/14/16Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
12/31/15Dry powder inhaler and inhalation actuated mechanism thereof
12/31/15Isoxazolidine derivatives
12/31/15Isoxazolidine derivatives
12/17/15Indolizine derivatives as phoshoinositide 3-kinases inhibitors
12/10/15Carbamate derivatives
12/10/15Aminoester derivatives
12/10/15Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
12/10/15Novel compounds
12/03/15Dry powder formulation comprising a phosphodiesterase inhibitor
12/03/15Kinase inhibitors
11/26/151-(2-fluorobiphenyl-4-yl)-cyclopropanecarboxylic acid derivatives for the treatment of down's syndrome
11/19/15Combination therapy for copd
11/12/15Use of magnesium stearate in dry powder formulations for inhalation
11/12/15Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy
10/29/15Aerosol formulation for copd
09/17/15Melatonin-based formulations for parenteral administration
07/23/15Process for preparing carrier particles for dry powders for inhalation
07/02/15Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
07/02/15Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
06/18/15Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
06/18/15Novel compounds
06/18/15Isochromene derivatives as phoshoinositide 3-kinases inhibitors
06/11/15Benzhydryl derivatives
06/11/15Heteroaryl derivatives
05/21/15Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
05/14/15Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
04/23/15Process for the preparation of a pde4 inhibitor
04/16/15Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
03/19/15Kinase inhibitors
03/05/151-phenylalkanecarboxylic acid derivatives for the treatment of alzheimer's disease and multiple sclerosis
02/26/15Isoxazolidine derivatives
02/26/15Kinase inhibitors
01/15/15Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation
01/15/15Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
12/25/14Process for the preparation of derivatives of 1-(2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid
12/25/141-phenyl-2-pyridinyl alkyl alcohol compounds as phosphodiesterase inhibitors
Patent Packs
12/11/14Aerosol formulation for copd
12/11/14Combination therapy for copd
12/11/14Kinase inhibitors
12/11/14Kinase inhibitors
12/11/14Process for the preparation of glycopyrronium chloride
11/20/14Kinase inhibitors
10/30/14Particle size reduction of an antimuscarinic compound
10/30/14Kinase inhibitors
06/26/141-phenyl-2-pyridinyl alkyl alcohol compounds as phosphodiesterase inhibitors
06/26/14Novel compounds
06/19/14Novel compounds
06/12/14Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
06/12/14Drug delivery device for the treatment of patients with respiratory diseases
06/12/14Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
06/05/14Novel compounds
Patent Packs
06/05/14Novel compounds
06/05/141-phenyl-2-pyridinyl alkyl alcohol derivatives as phosphodiesterase inhibitors
06/05/14Novel compounds
05/22/14Reconstituted pulmonary surfactants
05/22/14Synthetic apelin mimetics for the treatment of heart failure
05/22/14Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
05/15/14Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
05/15/14Novel polymorphs and salts
05/08/14Use of pulmonary surfactants in lung transplantation and methods thereof
03/13/14Isoxazolidine derivatives
03/06/14Aerosol inhalation device
02/27/14Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
01/16/14Inhibition of enzymes
12/19/13Method and system for the administration of a pulmonary surfactant by atomization
10/10/13Derivatives of 1-(2-halo-biphenyl-4-yl)-alkanecarboxylic acids for the treatment of neurodegenerative diseases
08/01/13Alkaloid aminoester derivatives and medicinal composition thereof
07/25/13Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
07/04/13Quinuclidine esters of 1-azaheterocyclylacetic acid as antimuscarinic agents, process for their preparation and medicinal compositions thereof
06/27/131-phenylalkanecarboxylic acid derivatives for the treatment of cognitive impairment
06/20/13Potentiation induced by pde4 inhibitors in the treatment of leukemia
06/13/13Kinase inhibitors
06/13/13Kinase inhibitors
06/13/13Pyrimidine derivatives and their use in the treatment of respiratory diseases such as copd
06/06/13Urea derivatives and their therapeutic use in the treatment of, inter alia, diseases of the respiratory tract
05/30/13Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
05/16/13Pyrimidine derivatives and their use in the treatment of respiratory diseases such as copd
04/25/13Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
04/11/13Crystalline microparticles of a beta-agonist coated with a fatty acid
03/28/13Reconstituted surfactants having improved properties
03/28/13Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
Social Network Patent Pack
03/14/13Novel compounds
02/21/13Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
02/07/13Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
02/07/13Pyrrolidine derivatives
01/10/131-phenyl-2-pyridinyl alkyl alcohol compounds as phosphodiesterase inhibitors
01/03/13Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
12/27/12Means for preventing and treating cellular death and their biological applications
11/29/12Topical formulation comprising a corticosteroid as active ingredient
11/01/12Alkaloid ester and carbamate derivatives and medicinal compositions thereof
09/20/12Isoxazolidine derivatives
Patent Packs
09/20/12Isoxazolidine derivatives
08/30/12Liquid propellant-free formulation comprising an antimuscarinic drug
08/02/12Novel caspase-2 inhibitors
07/19/12Optimised formulation of tobramycin for aerosolization
06/14/12Therapeutic combination comprising a pulmonary surfactant and antioxidant enzymes
05/31/12Glycine derivatives and medicinal compositions thereof
05/10/12Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
04/26/12Carbonate derivatives for the treatment of cough
04/12/12Triazolopyridine derivatives and their therapeutic use
04/05/12Use of magnesium stearate in dry powder formulations for inhalation
03/29/12Pyrimidopyridazine derivatives useful as p38 mapk inhibitors
03/08/12Metered-dose inhaler and using the same
03/08/12Metered-dose inhaler actuator, metered-dose inhaler and using the same
02/09/12Dry powder formulation comprising a phosphodiesterase inhibitor
02/09/12Pharmaceutical formulation comprising a phosphodiesterase inhibitor
02/02/12Pyrrolopyrimidinedione and its therapeutic use
01/26/12Method of administration of a pulmonary surfactant
01/26/121-(2-fluorobiphenyl-4-yl)-cyclopropanecarboxylic acid derivatives for the therapy of prion diseases
01/05/12Quinuclidine carbonate salts and medicinal composition thereof
12/29/11Quinuclidine carbonate salts and medicinal composition thereof
12/22/11Dry powder formulation comprising an antimuscarinic drug
12/22/11Alkaloid aminoester derivatives and medicinal compositions thereof
12/22/11Alkaloid aminoester derivatives and medicinal composition thereof
12/22/11Alkaloid aminoester derivatives and medicinal composition thereof
12/15/11Crystal form of glycopyrronium chloride
12/15/11Process for the preparation of glycopyrronium chloride
11/24/111-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
10/27/11Process for providing particles with reduced electrostatic charges
10/27/11Process for preparing carrier particles for dry powders for inhalation
10/27/111-(2-fluorobiphenyl-4-yl)-alkyl carboxylic acid derivatives for the therapy of transthyretin amyloidosis
Patent Packs
10/06/11Novel polymorphs and salts
09/01/11Optimised formulation of tobramycin for aerosolization
08/18/11Pyrrolidine derivatives
06/23/11Aerosol formulation for copd
06/23/11Combination therapy for copd
06/23/11Aerosol formulation for copd
06/23/11Combination therapy for copd
06/16/11Antibiotic microparticles for inhalation
06/16/11Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
06/16/11Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
06/02/11Therapeutic combination comprising a pulmonary surfactant and a steroid
05/05/11Pressurised metered dose inhalers (mdi)
04/28/11Particles comprising a salt of 8-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1h)-quinolinone having improved adhesion properties for powder formulations for inhalation
04/07/11Pharmaceutical aerosol formulations of formoterol and beclometasone dipropionate
03/24/11Therapeutic combination comprising a pulmonary surfactant and antioxidant enzymes
03/17/11Formoterol superfine formulation
03/17/11Isoxazolidine derivatives
02/24/118-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1h)-quinolinone hemi-fumarate
02/17/11Process for the preparation of derivatives of 1-(2- halobiphenyl-4-yl)-cyclopropanecarboxylic acid
01/06/11Reconstituted surfactant composition containing analogs of surfactant protein b (sp-b) and surfactant protein c (sp-c)
Social Network Patent Pack
10/28/10Inhalation particles comprising a salt of 8-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino] ethyl]-2(1h)-quinolinone and a corticosteroid
08/12/101-phenyl-2-pyridinyl alkyl alcohol compounds as phosphodiesterase inhibitors
07/22/10Nitroprotein biomarkers for copd
07/08/10Alkaloid aminoester derivatives and medicinal composition thereof
04/22/10Optimised formulation of tobramycin for aerosolization
04/22/101-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
03/04/10Micronized particles of low-dosage strength active agents for powder formulations for inhalation
02/25/10Pharmaceutical compositions containing an effervescent acid-base couple
02/11/10Quinuclidine carbonate salts and medicinal composition thereof
02/04/10Anti-amyloid immunogenic compositions, methods and uses
01/28/10Therapeutic combinations comprising a long acting dihydropyridine calcium-channel blocker and a statin
01/07/10Reconstituted surfactants having improved properties
12/31/09Process for the preparation of 8-hydroxy-5-[(1r)-1-hydroxy-2[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1h)-quinolinone monohydrochloride
12/17/09Pharmaceutical aerosol composition
12/17/09Process of preparing derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid
11/12/09Crystal form of 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1h)-quinolinone monohydrochloride
11/12/09Polymorph of 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1h)-quinolinone monohydrochloride
10/22/09Pressurised metered dose inhalers containing solutions of beta-2 agonists
10/15/09Phosphodiesterase-4 inhibitors belonging to the tertiary amine class
07/30/09Dry powder formulation comprising an anticholinergic drug
Social Network Patent Pack
07/23/09Anti-amyloid immunogenic compositions, methods and uses
07/16/09Pharmaceutical formulation comprising an anticholinergic drug
07/16/09Compositions comprising an antimuscarinic and a long-acting beta-agonist
07/02/09Compositions comprising pulmonary surfactants and a polymyxin having improved surface properties
07/02/09Ester derivatives as phosphodiesterase inhibitors
05/21/09Pharmaceutical solution formulations for pressurised metered dose inhalers
04/02/09Reconstituted surfactants having improved properties
03/19/09Synthetic pulmonary surfactant peptides
02/19/09Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
01/28/10Therapeutic combinations comprising a long acting dihydropyridine calcium-channel blocker and a statin
01/07/10Reconstituted surfactants having improved properties







ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Chiesi Farmaceutici S p a in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Chiesi Farmaceutici S p a with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###




';